Top

The International Journal of Cardiovascular Imaging

Published in:

Open Access 01-03-2019 | Review paper

Moving into the next era of PET myocardial perfusion imaging: introduction of novel ¹⁸F-labeled tracers

Authors: Rudolf A. Werner, Xinyu Chen, Steven P. Rowe, Constantin Lapa, Mehrbod S. Javadi, Takahiro Higuchi

Published in: The International Journal of Cardiovascular Imaging | Issue 3/2019

Abstract

The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel ¹⁸F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel ¹⁸F-labeled perfusion radiotracers will be discussed.

Available only for authorised users

Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG, American Heart Association Advocacy Coordinating C, Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular R, Intervention, Council on Clinical C, Council on E, Prevention, Stroke C (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (3):606–619. https://doi.org/10.1161/HHF.0b013e318291329a CrossRefPubMedPubMedCentral

Dunlay SM, Roger VL (2014) Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep 11(4):404–415. https://doi.org/10.1007/s11897-014-0220-x CrossRefPubMedPubMedCentral

Luscher TF (2018) Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation. Eur Heart J 39(1):1–4. https://doi.org/10.1093/eurheartj/ehx750 CrossRefPubMed

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128 CrossRefPubMed

Delepaul B, Robin G, Delmas C, Moine T, Blanc A, Fournier P, Roger-Rolle A, Domain G, Delon C, Uzan C, Boudjellil R, Carrie D, Roncalli J, Galinier M, Lairez O (2017) Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? ESC Heart Fail 4(2):99–104. https://doi.org/10.1002/ehf2.12131 CrossRefPubMedPubMedCentral

Lala A, Desai AS (2014) The role of coronary artery disease in heart failure. Heart Fail Clin 10(2):353–365. https://doi.org/10.1016/j.hfc.2013.10.002 CrossRefPubMed

Greenland P, Gaziano JM (2003) Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 349(5):465–473. https://doi.org/10.1056/NEJMcp023197 CrossRefPubMed

Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, Buechel RR, Cuocolo A, van Eck-Smit BL, Flotats A, Hacker M, Hindorf C, Kaufmann PA, Lindner O, Ljungberg M, Lonsdale M, Manrique A, Minarik D, Scholte AJ, Slart RH, Tragardh E, de Wit TC, Hesse B, European Association of Nuclear M (2015) EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging 42(12):1929–1940. https://doi.org/10.1007/s00259-015-3139-x CrossRefPubMedPubMedCentral

Rowe SP, Gorin MA, Pomper MG (2017) Imaging of prostate-specific membrane antigen using [(18)F]DCFPyL. PET Clin 12(3):289–296. https://doi.org/10.1016/j.cpet.2017.02.006 CrossRefPubMed

10.

Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K (2015) 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs. Ann Nucl Med 29(1):1–7. https://doi.org/10.1007/s12149-014-0898-6 CrossRefPubMed

11.

Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, Heller GV (2008) Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 15(6):745–753. https://doi.org/10.1007/BF03007355 CrossRefPubMed

12.

Bateman TM (2004) Cardiac positron emission tomography and the role of adenosine pharmacologic stress. Am J Cardiol 94(2A):19D–24D (discussion 24D-25D). https://doi.org/10.1016/j.amjcard.2004.04.013 CrossRef

13.

Werner RA, Wakabayashi H, Chen X, Hirano M, Shinaji T, Lapa C, Rowe SP, Javadi MS, Higuchi T (2018) Functional renal imaging with 2-deoxy-2-(18)F-fluorosorbitol PET in rat models of renal disorders. J Nucl Med 59(5):828–832. https://doi.org/10.2967/jnumed.117.203828 CrossRefPubMed

14.

Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P (2017) Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging 33(7):1021–1031. https://doi.org/10.1007/s10554-017-1084-4 CrossRefPubMedPubMedCentral

15.

Schindler TH, Quercioli A, Valenta I, Ambrosio G, Wahl RL, Dilsizian V (2014) Quantitative assessment of myocardial blood flow–clinical and research applications. Semin Nucl Med 44(4):274–293. https://doi.org/10.1053/j.semnuclmed.2014.04.002 CrossRefPubMed

16.

Schindler TH (2016) Myocardial blood flow: putting it into clinical perspective. J Nucl Cardiol 23(5):1056–1071. https://doi.org/10.1007/s12350-015-0372-4 CrossRefPubMed

17.

Rischpler C, Park MJ, Fung GS, Javadi M, Tsui BM, Higuchi T (2012) Advances in PET myocardial perfusion imaging: F-18 labeled tracers. Ann Nucl Med 26(1):1–6. https://doi.org/10.1007/s12149-011-0552-5 CrossRefPubMed

18.

Nakazato R, Berman DS, Alexanderson E, Slomka P (2013) Myocardial perfusion imaging with PET. Imaging Med 5(1):35–46. https://doi.org/10.2217/iim.13.1 CrossRefPubMedPubMedCentral

19.

Li Y, Zhang W, Wu H, Liu G (2014) Advanced tracers in PET imaging of cardiovascular disease. Biomed Res Int 2014:504532. https://doi.org/10.1155/2014/504532 CrossRefPubMedPubMedCentral

20.

Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG (1999) Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 40(11):1848–1856PubMed

21.

Rauch B, Helus F, Grunze M, Braunwell E, Mall G, Hasselbach W, Kubler W (1985) Kinetics of 13N-ammonia uptake in myocardial single cells indicating potential limitations in its applicability as a marker of myocardial blood flow. Circulation 71(2):387–393CrossRef

22.

Kobayashi R, Chen X, Werner RA, Lapa C, Javadi MS, Higuchi T (2017) New horizons in cardiac innervation imaging: introduction of novel (18)F-labeled PET tracers. Eur J Nucl Med Mol Imaging 44(13):2302–2309. https://doi.org/10.1007/s00259-017-3828-8 CrossRefPubMed

23.

Ducharme J, Goertzen AL, Patterson J, Demeter S (2009) Practical aspects of 18F-FDG PET when receiving 18F-FDG from a distant supplier. J Nucl Med Technol 37(3):164–169. https://doi.org/10.2967/jnmt.109.062950 CrossRefPubMed

24.

Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S, Samnick S, Javadi M, Schwaiger M, Nekolla SG, Higuchi T (2015) Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG. J Nucl Med 56(9):1429–1433. https://doi.org/10.2967/jnumed.115.158493 CrossRefPubMed

25.

Maddahi J, Packard RR (2014) Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med 44(5):333–343. https://doi.org/10.1053/j.semnuclmed.2014.06.011 CrossRefPubMedPubMedCentral

26.

Hirano M, Werner RA, Higuchi T (2018) A New era of myocardial perfusion imaging: 18F PET Tracer. ANC. https://doi.org/10.17996/anc.18-00056 CrossRef

27.

Schuler F, Casida JE (2001) The insecticide target in the PSST subunit of complex I. Pest Manag Sci 57(10):932–940. https://doi.org/10.1002/ps.364 CrossRefPubMed

28.

Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, Ziegler SI, Casebier DS, Robinson SP, Schwaiger M (2008) Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med 49(4):630–636. https://doi.org/10.2967/jnumed.107.044727 CrossRefPubMed

29.

Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, Radeke H, Azure M, Purohit A, Casebier DS, Robinson SP (2007) BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol 14(6):789–798. https://doi.org/10.1016/j.nuclcard.2007.07.008 CrossRefPubMed

30.

Yu M, Bozek J, Guaraldi M, Kagan M, Azure M, Robinson SP (2010) Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits. J Nucl Cardiol 17(4):631–636. https://doi.org/10.1007/s12350-010-9221-7 CrossRefPubMed

31.

Pagnanelli RA, Basso DA (2010) Myocardial perfusion imaging with 201Tl. J Nucl Med Technol 38(1):1–3. https://doi.org/10.2967/jnmt.109.068593 CrossRefPubMed

32.

Higuchi T, Nekolla SG, Huisman MM, Reder S, Poethko T, Yu M, Wester HJ, Casebier DS, Robinson SP, Botnar RM, Schwaiger M (2008) A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med 49(10):1715–1722. https://doi.org/10.2967/jnumed.108.053967 CrossRefPubMed

33.

Higuchi T, Fukushima K, Rischpler C, Isoda T, Javadi MS, Ravert H, Holt DP, Dannals RF, Madar I, Bengel FM (2011) Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion. J Nucl Med 52(6):965–969. https://doi.org/10.2967/jnumed.110.085993 CrossRefPubMed

34.

Rischpler C, Higuchi T, Fukushima K, Javadi MS, Merrill J, Nekolla SG, Bravo PE, Bengel FM (2012) Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: normal values and significance as a diagnostic and prognostic marker. J Nucl Med 53(5):723–730. https://doi.org/10.2967/jnumed.111.097600 CrossRefPubMed

35.

Sherif HM, Saraste A, Weidl E, Weber AW, Higuchi T, Reder S, Poethko T, Henriksen G, Casebier D, Robinson S, Wester HJ, Nekolla SG, Schwaiger M (2009) Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats. Circ Cardiovasc Imaging 2(2):77–84. https://doi.org/10.1161/CIRCIMAGING.108.815423 CrossRefPubMed

36.

Guehl NJ, Normandin MD, Wooten DW, Rozen G, Sitek A, Ruskin J, Shoup TM, Ptaszek LM, El Fakhri G, Alpert NM (2017) Single-scan rest/stress imaging: validation in a porcine model with (18)F-Flurpiridaz. Eur J Nucl Med Mol Imaging 44(9):1538–1546. https://doi.org/10.1007/s00259-017-3684-6 CrossRefPubMed

37.

Sherif HM, Nekolla SG, Saraste A, Reder S, Yu M, Robinson S, Schwaiger M (2011) Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. J Nucl Med 52(4):617–624. https://doi.org/10.2967/jnumed.110.083196 CrossRefPubMed

38.

Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, Huisman M, Poethko T, Schuster T, Yu M, Robinson S, Casebier D, Henke J, Wester HJ, Schwaiger M (2009) Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation 119(17):2333–2342. https://doi.org/10.1161/CIRCULATIONAHA.108.797761 CrossRefPubMed

39.

Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M (2011) Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med 52(9):1490–1498. https://doi.org/10.2967/jnumed.111.092528 CrossRefPubMed

40.

Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J (2014) Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. J Nucl Med 55(9):1438–1444. https://doi.org/10.2967/jnumed.114.141093 CrossRefPubMedPubMedCentral

41.

Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D (2013) Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol 61(4):469–477. https://doi.org/10.1016/j.jacc.2012.11.022 CrossRefPubMed

42.

Maddahi J, Czernin J, Berman D, Taillefer R, Devine M, Lazewatsky J, Bhat G, Washburn D (2011) Comparison of flurpiridaz F 18 PET injection and Tc-99m labeled SPECT myocardial perfusion imaging for identifying severity and extent of stress induced myocardial ischemia in phase 2 clinical trials. J Nucl Med 52(no:supplement 1):444

43.

Bateman TM, Maddahi J, Udelson J, Beanlands R, Knuuti J, Heller G, Berman D, Lazewatsky J, Orlandi C (2016) Improved assessment of cad in obese subjects with flurpiridaz F18 PET myocardial perfusion imaging: a subset analysis of the flurpiridaz F18 301 phase 3 study. JACC 67(13 Supplement):1578CrossRef

44.

https://www.medicaldevice-network.com/news/ge-healthcare-initiates-new-phase-iii-trial-flurpiridaz-detect-cad/. Last downloaded August 4, 2018

45.

https://clinicaltrials.gov/ct2/show/study/NCT03354273-contacts. An international study to evaluate diagnostic efficacy of flurpiridaz (18F) injection PET MPI in the detection of coronary artery disease (CAD) last downloaded August 5, 2018

46.

Madar I, Ravert H, Nelkin B, Abro M, Pomper M, Dannals R, Frost JJ (2007) Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging 34(12):2057–2065. https://doi.org/10.1007/s00259-007-0500-8 CrossRefPubMed

47.

Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, Frost JJ, Hare JM (2006) Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med 47(8):1359–1366PubMed

48.

Sinusas AJ, Shi Q, Saltzberg MT, Vitols P, Jain D, Wackers FJ, Zaret BL (1994) Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med 35(4):664–671CrossRef

49.

Madar I, Ravert H, Dipaula A, Du Y, Dannals RF, Becker L (2007) Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med 48(6):1021–1030. https://doi.org/10.2967/jnumed.106.038778 CrossRefPubMed

50.

Werner RA, Wakabayashi H, Bauer J, Schütz C, Zechmeister C, Hayakawa N, Javadi MS, Lapa C, Jahns R, Süleyman E, Jahns V, Higuchi T (2018) Longitudinal 18F-FDG PET imaging in a rat model of autoimmune myocarditis. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jey119

51.

Kim DY, Kim HS, Reder S, Zheng JH, Herz M, Higuchi T, Pyo AY, Bom HS, Schwaiger M, Min JJ (2015) Comparison of 18F-labeled fluoroalkylphosphonium cations with 13N-NH3 for PET myocardial perfusion imaging. J Nucl Med 56(10):1581–1586. https://doi.org/10.2967/jnumed.115.156794 CrossRefPubMed

52.

Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, Cerqueira MD, deKemp RA, DePuey EG, Dilsizian V, Dorbala S, Ficaro EP, Garcia EV, Gewirtz H, Heller GV, Lewin HC, Malhotra S, Mann A, Ruddy TD, Schindler TH, Schwartz RG, Slomka PJ, Soman P, Di Carli MF, Directors SCCBo, Directors ABo (2018) Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med 59 (2):273–293. https://doi.org/10.2967/jnumed.117.201368 CrossRefPubMed

53.

Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L (2012) ‘United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59(1 Suppl 1):A7. https://doi.org/10.1053/j.ajkd.2011.11.015e1-420.CrossRefPubMed

54.

Al-Mallah MH, Hachamovitch R, Dorbala S, Di Carli MF (2009) Incremental prognostic value of myocardial perfusion imaging in patients referred to stress single-photon emission computed tomography with renal dysfunction. Circ Cardiovasc Imaging 2(6):429–436. https://doi.org/10.1161/CIRCIMAGING.108.831164 CrossRefPubMed

55.

Mc Ardle BA, Davies RA, Chen L, Small GR, Ruddy TD, Dwivedi G, Yam Y, Haddad H, Mielniczuk LM, Stadnick E, Hessian R, Guo A, Beanlands RS, deKemp RA, Chow BJ (2014) Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant. Circ Cardiovasc Imaging 7(6):930–937. https://doi.org/10.1161/CIRCIMAGING.114.002184 CrossRefPubMed

56.

Werner RA, Chen X, Hirano M, Rowe SP, Lapa C, Javadi M, Higuchi T (2018) SPECT vs. PET in cardiac innervation imaging: clash of the titans. Clin Transl Imaging 6(4):293–303CrossRef

57.

Werner RA, Maya Y, Rischpler C, Javadi MS, Fukushima K, Lapa C, Herrmann K, Higuchi T (2016) Sympathetic nerve damage and restoration after ischemia-reperfusion injury as assessed by (11)C-hydroxyephedrine. Eur J Nucl Med Mol Imaging 43(2):312–318. https://doi.org/10.1007/s00259-015-3171-x CrossRefPubMed

58.

Lindner O, Burchert W, Schafer W, Hacker M (2017) Myocardial perfusion SPECT 2015 in Germany. Results of the 7(th) survey. Nuklearmedizin 56(1):31–38. https://doi.org/10.3413/Nukmed-0858-16-10 CrossRefPubMed

Title: Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18F-labeled tracers
Authors: Rudolf A. Werner
Xinyu Chen
Steven P. Rowe
Constantin Lapa
Mehrbod S. Javadi
Takahiro Higuchi
Publication date: 01-03-2019
Publisher: Springer Netherlands
Published in: The International Journal of Cardiovascular Imaging / Issue 3/2019
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-018-1469-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Moving into the next era of PET myocardial perfusion imaging: introduction of novel ¹⁸F-labeled tracers

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Impact of tissue protrusion after coronary stenting in patients with ST-segment elevation myocardial infarction

Cardiac magnetic resonance based deformation imaging: role of feature tracking in athletes with suspected arrhythmogenic right ventricular cardiomyopathy

Correlation of FFR-derived from CT and stress perfusion CMR with invasive FFR in intermediate-grade coronary artery stenosis

Proteinuria is an independent predictor of rapid progression of mild to moderate aortic stenosis in patients with preserved renal function

Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds

Prospective evaluation of left atrial function and late gadolinium enhancement with 3 T MRI in patients with atrial fibrillation before and after catheter ablation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page